Pasithea Therapeutics Corp.(KTTA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Not in ranked universe
Below size threshold
Quality rankings require at least $50M annual revenue or $250M total assets to filter out micro-caps and shell companies. This company reported $0.5M in revenue.
Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.
KTTA Stock Analysis & AI Quality Score
AI stock analysis and institutional research for Pasithea Therapeutics Corp. (KTTA), a Healthcare sector company. KTTA is not currently included in 13F Pro's AI-ranked quality universe — quality rankings require at least $50m annual revenue or $250m total assets to filter out micro-caps and shell companies. this company reported $0.5m in revenue. Based on the latest XBRL financial filings (Q1 2026), Pasithea Therapeutics Corp. reports net income of $-2.9M, free cash flow of $-4.8M. Top institutional holders of KTTA by reported 13-F value include JANUS HENDERSON GROUP PLC, ADAGE CAPITAL PARTNERS GP, L.L.C., Squadron Capital Management, based on the most recent SEC filings. KTTA trades on the Nasdaq exchange and files with the SEC under CIK 1841330. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate KTTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Pasithea Therapeutics Corp. directly from SEC EDGAR.
Net Income
Q1 2026
$-2.9M
Free Cash Flow
Q1 2026
$-4.8M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
Net Income
-46.6% YoYOperating Income
-65.7% YoYEPS (Diluted)
-6513.6% YoYTotal Assets
+33.3% YoYOp. Cash Flow
-4.5% YoY| Metric | FY 2025 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|
| Revenue | — | $486.6K +3130.4% | $15.1K | — |
| Net Income | $-20.4M -46.6% | $-13.9M -541.2% | $-2.2M | — |
| Operating Income | $-20.9M -65.7% | $-12.6M -179.3% | $-4.5M | — |
| EPS (Diluted) | $-2.91 -6513.6% | $-0.04 -746.2% | $-0.01 | — |
| Total Assets | $60.2M +33.3% | $45.2M -15.3% | $53.3M +21403.9% | $248.0K |
| Operating Cash Flow | $-15.2M -4.5% | $-14.6M -358.8% | $-3.2M | — |
AI Insight: KTTA Financial Trends
Pre-revenue biotech burning cash consistently; Q4 2025 equity spike suggests capital raise, but operating losses persist.
• Operating losses stable at $3–4M quarterly Q2 2024–Q3 2025, then spiked to $10M in Q4 2025, moderating to $5M in Q1 2026.
• Equity jumped from $12M (Q3 2025) to $55M (Q4 2025), indicating significant capital raise; stabilized at $55M through Q1 2026.
• Operating cash flow negative every quarter, ranging $3–5M burn since Q1 2025, with no revenue visibility in available data.
⚠ Runway from $55M equity with ~$4M quarterly burn suggests ~14 quarters of funding; monitor for next financing need.
⚠ No revenue reported across all eight quarters; clinical-stage risk remains high without evidence of commercialization.
AI Insight: KTTA Ratio Trends
Pasithea's losses narrowed dramatically in Q1 2026, with ROE improving to −20.9% from −73.2% in Q4 2025, signaling a fundamental shift toward profitability.
• ROE improved 52.3pp from Q4 2025 (−73.2%) to Q1 2026 (−20.9%), largest single-quarter gain in available history.
• ROA similarly strengthened 46.7pp over same period, from −67.1% to −20.4%, suggesting operational losses are contracting sharply.
• TTM ROE and ROA remain deeply negative at −36.0% and −35.0%, reflecting accumulated losses from prior quarters; recent momentum has not yet offset full-year drag.
⚠ Q1 2026 ROIC of −35.6% remains well below Q4 2025 (−74.3%), but still negative; sustain improvement trajectory to confirm turnaround.
⚠ Operating margin and net profit margin data missing across all periods; cannot assess gross profitability or operating leverage drivers.
Get alerted when KTTA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Pasithea Therapeutics Corp. including:
Top Institutional Holders of KTTA
JANUS HENDERSON GROUP PLC
$1.6M2,100,000 shADAGE CAPITAL PARTNERS GP, L.L.C.
$1.6M2,100,000 shSquadron Capital Management LLC
$1.6M2,100,000 shVivo Capital, LLC
$1.6M2,100,000 shAMERIPRISE FINANCIAL INC
$1.0M1,350,896 shCable Car Capital, LP
$894.9K1,206,379 shStonepine Capital Management, LLC
$616.7K831,301 shAdvisorShares Investments LLC
$250.4K337,508 shPersistent Asset Partners Ltd
$215.5K290,555 shGEODE CAPITAL MANAGEMENT, LLC
$77.1K103,985 sh
| Fund | Value | Shares |
|---|---|---|
| JANUS HENDERSON GROUP PLC | $1.6M | 2,100,000 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $1.6M | 2,100,000 |
| Squadron Capital Management LLC | $1.6M | 2,100,000 |
| Vivo Capital, LLC | $1.6M | 2,100,000 |
| AMERIPRISE FINANCIAL INC | $1.0M | 1,350,896 |
| Cable Car Capital, LP | $894.9K | 1,206,379 |
| Stonepine Capital Management, LLC | $616.7K | 831,301 |
| AdvisorShares Investments LLC | $250.4K | 337,508 |
| Persistent Asset Partners Ltd | $215.5K | 290,555 |
| GEODE CAPITAL MANAGEMENT, LLC | $77.1K | 103,985 |
More Healthcare Companies
View all Healthcare →Put KTTA on your watchlist
Track score changes the day Pasithea Therapeutics Corp. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is KTTA a good stock to buy?
13F Pro's AI-powered analysis of Pasithea Therapeutics Corp. (KTTA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for KTTA are available on the KTTA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own KTTA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling KTTA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Pasithea Therapeutics Corp.'s investment landscape.